Hematologic Cancers

Selinexor Trials Move Nuclear Suppressor Protein-Export Inhibition Closer to the Clinic for Multiple Myeloma

Selinexor Trials Move Nuclear Suppressor Protein-Export Inhibition Closer to the Clinic for Multiple Myeloma

By

XPO1 inhibition restores the ability of intranuclear tumor suppressor genes to disrupt oncoproteins; it is emerging as a promising new investigational strategy in MM.

Can Treatments for Childhood ALL Alter the Gut Microbiome?

Can Treatments for Childhood ALL Alter the Gut Microbiome?

By

New research confirms that gut microbiome dysbiosis is present in survivors of childhood acute lymphoblastic leukemia.

Gly101Val Mutation Directly Causes Resistance to Venetoclax

Gly101Val Mutation Directly Causes Resistance to Venetoclax

By

Researchers identified a single heterozygous nucleotide variant that confers resistance to venetoclax, and it's a mutation that may be detected years before clinical relapse occurs.

Molecular Mechanisms Underlying Immunosurveillance in Multiple Myeloma Identified

Molecular Mechanisms Underlying Immunosurveillance in Multiple Myeloma Identified

By

Investigators identify a novel role of the genes located on chr17p13 in the induction of apoptosis in multiple myeloma.

Continuous Therapy May Be Beneficial in Patients With Newly Diagnosed Multiple Myeloma

Continuous Therapy May Be Beneficial in Patients With Newly Diagnosed Multiple Myeloma

By

Continuous therapy appears to be the preferred treatment modality in newly diagnosed patients with multiple myeloma (MM).

EUTOS Long-Term Survival Score Outperforms Sokal in TKI-Treated CML

EUTOS Long-Term Survival Score Outperforms Sokal in TKI-Treated CML

By

EUTOS long-term survival score better predicted prognosis for those with chronic myeloid leukemia who had been treated with TKIs—especially among elderly patients.

Daratumumab Combination: New Standard of Care in Transplant-Ineligible Multiple Myeloma

Daratumumab Combination: New Standard of Care in Transplant-Ineligible Multiple Myeloma

By

The findings may support the triplet regimen as a new standard of care for these patients, according to Dr Facon.

Ibrutinib + Rituximab Reportedly Superior to Current Standard of Care in Younger Patients With CLL

Ibrutinib + Rituximab Reportedly Superior to Current Standard of Care in Younger Patients With CLL

By

Three-year outcomes reveal a new standard of care in patients with CLL who are younger than 70.

Rivaroxaban Reduced VTE and VTE-Related Death in Patients With Cancer: Results of the CASSINI Study

Rivaroxaban Reduced VTE and VTE-Related Death in Patients With Cancer: Results of the CASSINI Study

By

Although results indicated rivaroxaban decreased the risk of VTE and VTE-related death in patients with cancer, the benefit was not maintained at study conclusion.

CHIP Associated with Poorer Outcomes in Lymphoma

CHIP Associated with Poorer Outcomes in Lymphoma

By

Clonal hematopoiesis of indeterminate potential is associated with shorter overall and event-free survival after autologous transplant in lymphoma.

MCARH171, a BCMA-Targeted CAR-T in Relapsed/Refractory Multiple Myeloma: Phase 1 Readout

MCARH171, a BCMA-Targeted CAR-T in Relapsed/Refractory Multiple Myeloma: Phase 1 Readout

By

A readout of results from a phase 1 trial featuring MCARH171 demonstrates the potential of the human-derived BCMA-targeted CAR-T for R/R MM.

CAR-T Cells Successfully Manufactured at Point-of-Care

CAR-T Cells Successfully Manufactured at Point-of-Care

By

CAR-T cells targeting CD19 and CD20 were successfully and reproducibly produced at the point-of-care within 14 days.

Changes in Microbial Diversity in Patients Undergoing Autologous Hematopoietic Stem Cell Transplant

Changes in Microbial Diversity in Patients Undergoing Autologous Hematopoietic Stem Cell Transplant

By

Loss of intestinal bacterial diversity in patients undergoing AHCT may be comparable to reductions experienced by patients undergoing alloHCT.

Nanjing Legend Biotech Adds More Patient Data for BCMA CAR-T

Nanjing Legend Biotech Adds More Patient Data for BCMA CAR-T

By

BCMA expression did not correlate with clinical response.

JCARH125 CAR-T "Highly Active" in Relapsed/Refractory Multiple Myeloma

JCARH125 CAR-T "Highly Active" in Relapsed/Refractory Multiple Myeloma

By

Patients saw a deepening of responses over time.

Further Investigation of AMG 420 in Relapsed/Refractory Multiple Myeloma Warranted

Further Investigation of AMG 420 in Relapsed/Refractory Multiple Myeloma Warranted

By

AMG 420 is an anti-B cell maturation antigen bispecific T cell engager antibody construct.

Early Findings Indicate P-BCMA-101 May Be Effective, Tolerable in R/R Multiple Myeloma

Early Findings Indicate P-BCMA-101 May Be Effective, Tolerable in R/R Multiple Myeloma

By

Early results of phase 1, dose-escalation trial demonstrate efficacy and safety of P-BCMA-101 CAR-T cell therapy in patients with R/R MM.

REGN5458 Demonstrates Antitumor Activity in Myeloma Across Various Preclinical Models

REGN5458 Demonstrates Antitumor Activity in Myeloma Across Various Preclinical Models

By

The investigational antibody construct exploits the power of native effector T cells, supporting antitumor activity shortly after administration.

Synchronized Delivery of Proteasome and Bone Marrow Microenvironment Inhibitors in MM

Synchronized Delivery of Proteasome and Bone Marrow Microenvironment Inhibitors in MM

By

Restricting MM cancer cells from making contact with the bone marrow microenvironment may be achieved through the delivery of inhibitors through nanoparticles.

Allogeneic BCMA-Directed CAR-T in Multiple Myeloma: Slated to Hit Phase 1 in 2019

Allogeneic BCMA-Directed CAR-T in Multiple Myeloma: Slated to Hit Phase 1 in 2019

By

The construct from Allogene has been engineered to avoid the serious immune-related complications linked to allogeneic transplantation.

Front-Line Bendamustine Combination Linked With Stem Cell Mobilization Failure in MCL

Front-Line Bendamustine Combination Linked With Stem Cell Mobilization Failure in MCL

By

Bendamustine-rituximab combination increased risk for day 1 stem cell mobilization failure

ASH 2018: Novel Therapies in Blood Cancers

ASH 2018: Novel Therapies in Blood Cancers

Mohamad Mohty, MD, PhD, discusses the latest research at ASH 2018.

Positive Phase 2 SY-1425 Results for AML and MDS

Positive Phase 2 SY-1425 Results for AML and MDS

Nancy Simonian, MD, discusses the results at ASH 2018.

Results From LYRA Phase 2 Study of Frontline Multiple Myeloma Therapy

Results From LYRA Phase 2 Study of Frontline Multiple Myeloma Therapy

Habte Yimer, MD, discusses his findings at the ASH 2018 meeting.

Drug Sensitivity Is Genotype-Dependent: Study

Drug Sensitivity Is Genotype-Dependent: Study

By

Genetically defined mouse models of AEL could help researchers find novel treatment approaches.

Phase 3 POLLUX Study: Three-Year Follow-Up

Phase 3 POLLUX Study: Three-Year Follow-Up

Nizar Bahlis, MD, discusses his findings at the ASH 2018 meeting.

ASH 2018: Practice-Changing Findings on Treatment of Lymphoma

ASH 2018: Practice-Changing Findings on Treatment of Lymphoma

John Burke, MD, discusses the latest research at ASH 2018.

New Standard of Care in CLL Proposed for Older Patients

New Standard of Care in CLL Proposed for Older Patients

By

Although PFS with ibrutinib-containing regimens was favorable compared with bendamustine rituximab, overall survival was not different across the study arms.

The Biology and Genetics of Acute Leukemia: Two New Resources

The Biology and Genetics of Acute Leukemia: Two New Resources

Charles G. Mullighan, MBBS (Hons), MSc, MD, discusses the latest research out of St Jude at ASH 2018.

Luspatercept Reduced RBC Transfusion Dependence in Lower-Risk Patients With Myelodysplastic Syndromes

Luspatercept Reduced RBC Transfusion Dependence in Lower-Risk Patients With Myelodysplastic Syndromes

By

Findings from the MEDALIST trial revealed a significant reduction in transfusion burden for patients being treated with luspatercept compared with placebo

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs